Highlight
- Long-term, low-dose capecitabine reduces the incidence of keratinocyte carcinomas in patients with refractory cutaneous field cancerization.
- The treatment is generally well tolerated, with a low discontinuation rate due to toxicity.
- Patient-reported satisfaction is high, with most preferring capecitabine over alternative therapies.
- Statistical analysis showed significant reduction in skin cancer surgeries at 2 years, emphasizing sustained clinical benefit.
Study Background
